Bullboard Post History

by ScienceFirst

Order by:

T.PYR	RE:Reflective of the stock You wonder why Tamarackflop only lives in the past. Maybe because... February 4, 2023
V.TLT	RE:RE:Merck’s Keytruda brings in $21 Billion. TDON ... TLT's logo is "Destroying cancer at speed oflight... February 3, 2023
V.TLT	RE:RE:RE:Merck’s Keytruda brings in $21 Billion. It's the big pharmas that had the ability to scout the world for the best... February 3, 2023
V.TLT	RE:RE:Quick poll Well said Cancer.Slayer. Princess Margaret Cancer Center, the only Cancer... February 2, 2023
V.TLT	RE:Merck in NSCLC At ESMO 2022, Merck's Keytruda was linked to a five-year... February 2, 2023
V.TLT	Merck in NSCLC FDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment... February 2, 2023
V.TLT	RE:RE:RE:RE:excellent ! Excellent ! NEWS Exact Cancer Slayer. They to stick with what was initially accepted... February 2, 2023
V.TLT	RE:Visibility It's more a question of gaining visibility, assessing interest, etc ... &... February 2, 2023
V.TLT	RE:RE:RE:Interpretation of latest NR We recently discussed that submission to the FDA is not material. Never... February 2, 2023
V.TLT	RE:Interpretation of latest NR N0ta ... You're wrong. And you don't understand how the... February 2, 2023
V.TLT	RE:RE:RE:RE:We’re now entering the visibility zone 25 patients @450-days. And no plot theories here. It's not the... February 2, 2023
V.TLT	RE:We’re now entering the visibility zone These conferences will give much needed feedback to Theralase, so when... February 2, 2023
V.TLT	RE:We’re now entering the visibility zone What's interesting is that 100% of urologists know BCG, given how long... February 2, 2023
V.TLT	RE:We’re now entering the visibility zone Visibility to an audience (urologists) that can influence big pharmas... February 2, 2023
V.TLT	We’re now entering the visibility zone ASCO-GU, now AUA. Soon CUA and EUA. Hopefully, we'll have some... February 2, 2023
T.PYR	RE:Press Release Less CAPEX than current industry, for similar output. that at least two (2)... February 2, 2023
V.TLT	FDA reviving an old therapy of 20y ago The FDA is not afraid of innovating. This example reminds me the... February 1, 2023
V.TLT	FDA chase down a pharma company and ask them apply for a NDA Everything is possible ... Could be our case one of these days, given... February 1, 2023
V.TLT	Eli Lilly grabs Loxo Oncology for $8B A bit old (2019), but it shows that there are first that are worth much. Eli... February 1, 2023
V.TLT	RE:Moving to NASDAQ once FDA designation is granted I remember in 2017 (??) seeing a biotech flying from 0.75$ right through 8... February 1, 2023

Become a member today, It's free!

Bullboard Post History

by ScienceFirst

RE:Reflective of the stock

RE:RE:Merck’s Keytruda brings in $21 Billion.

RE:RE:RE:Merck’s Keytruda brings in $21 Billion.

RE:RE:Quick poll

RE:Merck in NSCLC

Merck in NSCLC

RE:RE:RE:RE:excellent ! Excellent ! NEWS

RE:Visibility

RE:RE:RE:Interpretation of latest NR

RE:Interpretation of latest NR

RE:RE:RE:RE:We’re now entering the visibility zone

RE:We’re now entering the visibility zone

RE:We’re now entering the visibility zone

RE:We’re now entering the visibility zone

We’re now entering the visibility zone

RE:Press Release

FDA reviving an old therapy of 20y ago

FDA chase down a pharma company and ask them apply for a NDA

Eli Lilly grabs Loxo Oncology for $8B

RE:Moving to NASDAQ once FDA designation is granted

Featured News Links

Options Trading for Retiring: Key Strategies in Balancing Retirement Income

One Property, One Focus on Advancing this Gold Project in Ontario

Featured Company

ReGen III Corp. V.GIII

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard Post History

by ScienceFirst

Featured News Links

Featured Company